Alpha Teknova, Inc. - Common Stock (TKNO)

Biopharma demand lifted results and a $46 million raise bolstered the balance sheet.

Alpha Teknova (NASDAQ:TKNO) raised its 2026 revenue guidance after reporting a second consecutive quarter of record revenue, as demand for custom products from biopharma, life science tools and diagnostics customers helped drive 22% year-over-year growth. The company now expects full-year revenue o

Alpha Teknova (NASDAQ:TKNO) Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve. Speaking at the S

Alpha Teknova (NASDAQ:TKNO) reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million for its highest quarterly revenue in the company’s 30-year history. The company raised its full-year revenue outlook, citing first-half performance and confidence in the second half

Alpha Teknova (TKNO) Q1 2026 Earnings Transcript

Alpha Teknova (TKNO) Q3 2025 Earnings Transcript